Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Thyroid Cancer Clinical Trials

A listing of Thyroid Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (146) clinical trials

Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer

The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed + paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer.


Studying Thyroid Cancer and Other Thyroid Diseases in Participants Who Were Children in Ukraine During the Chernobyl Nuclear Power Plant Accident

OBJECTIVES: - Carry out valid and credible assessments of the early and late morphologic and functional changes in the thyroid glands of individuals exposed to radiation from radioactive materials released as a result of the Chernobyl nuclear power plant accident in 1986. - Examine other possible risk factors, including dietary ...

Phase N/A

Influence of Thyroid Hormones on the Woundhealing Process

Main goal of this clinical investigation is to investigate different cytokines in wound fluids of euthyroid vs. hypothyroid patients. As a primary endpoint we want to evaluate if different cytokine levels in euthyroid vs. hypothyroid patients exist and to what extent these cytokines differ. Our targeted cytokines are: IL6, IL10, ...

Phase N/A

Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases

Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.

Phase N/A

11C-Acetate PET/CT Non-FDG-Avid Tumors

Recent publications have suggested the use of 11C-acetate as another PET tracer for tumor imaging. The accumulation of 11C-acetate in tumor cells is related to the highly active lipid metabolism in the cell membrane associated with tumor growth. 11C-acetate is channeled into the tricarboxylic acid cycle via acetyl coenzyme A ...

Phase N/A

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Background Anti PD1/PDL1 therapies have had clinical success in a minority of unselected patients across multiple tumor types While many questions remain about optimal PD1/PDL1 staining techniques to pre-select responders, less focus is being place on how to optimize responses in a broader cohort of patients Emerging preclinical and clinical ...


Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification HER2 Mutation/Amplification HER3/4 Mutation or KRAS Mutation

Objectives Primary Objectives: To evaluate the safety and tolerability of neratinib when combined with one of the following agents Arm 1: Everolimus (mTOR inhibitor) Arm 2: Palbociclib (CDK 4/6 inhibitor) Arm 3: Trametinib (MEK inhibitor) To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of neratinib combination therapy. ...


Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

This is a multinational, multicenter, non-interventional (observational) and prospective study. European countries where vandetanib is on the market will participate in the study. This study is being conducted to fulfil the specific obligation post-authorisation measure for the conditional marketing authorisation. It is carried on to confirm in real life conditions ...

Phase N/A

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

This randomized Phase II trial will compare the progression-free survival (PFS) of sorafenib and everolimus versus sorafenib alone in patients with radioactive iodine refractory hurthle cell thyroid cancer. Prior studies have shown that the median PFS is generally around 4.5 months for sorafenib alone in this disease population. It is ...


Prospective Non-interventional Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

This is a non-interventional, multi center post-authorization safety study that includes all patients diagnosed as Unresectable Differentiated Thyroid Carcinoma (DTC) and treated with Sorafenib within a certain period. The investigator should have made the choice of treatment (NEXAVAR) according with the Japanese Package Insert prior to enrolling the patient in ...

Phase N/A